We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Catarina Fontanella MD

Catarina Fontanella MD

Trainee in Medical Oncology, University of Udine, Udine, Italy; Research Fellow, German Breast Group, Neu-Isenburg, Germany

Caterina Fontanella gained her Medical Degree in March 2010 from the University of Trieste, Italy. During my pre-graduate internships she has gained experience in laboratory techniques and preclinical studies. Since 2011, Dr. Fontanella works as trainee doctor at the Department of Medical Oncology, University Hospital of Udine, Italy. Over the last 3 years, she has gained experience in the management of out- and in-patients with a wide range of adult solid tumors and in the administration of anticancer agents and management of drug-related adverse events. Moreover, she is co-investigator for several clinical trials, including pharmaceutical company sponsored phase I, II, and III trials. From January 2013 to March 2014, she worked as a Research Fellow at the German Breast Group (Neu-Isenburg, Germany). During her fellowship she has increased her experience in clinical trials design and management, data managing, investigational drugs administration, and publishing process. In November 2013 she were been selected as the recipient of the Monica Boscolo Research Grant 2013 with a project focused on the predictive value of O6-methylguanine-DNA methyltransferase (MGMT) promoter gene methylation in triple-negative breast cancer patients receiving alkylating agents. She has also been selected to attend the FLIMS Workshop in Clinical Trials in June 2014.

Recent Contributions to PracticeUpdate:

  1. Neoadjuvant Carboplatin in Early Breast Cancer